Otonomy (NASDAQ:OTIC) Receives New Coverage From Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Receives New Coverage From Analysts at StockNews.com
Investment analysts at StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research note issued on Thursday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
股票新聞網的投資分析師開始對股票的報導 性 (納斯達克:奧迪 — 獲得評級) 在星期四發出的一份研究報告中。該經紀公司對該生物製藥公司的股票設定了「持有」評級。
Separately, Piper Sandler cut Otonomy from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $3.00 to $0.50 in a research report on Thursday, October 13th.
另外，派珀·桑德勒（Piper Sandler）在 10 月 13 日（星期四）的一份研究報告中，將 Otonomy 從「超重」評級降至「中性」評級，並將股票的目標價格從 3.00 美元降至 0.50 美元。
Otonomy Stock Down 7.5 %
音量庫存下降 7.5%
Shares of NASDAQ OTIC opened at $0.11 on Thursday. The stock's 50 day moving average price is $0.11 and its two-hundred day moving average price is $0.32. Otonomy has a 52-week low of $0.06 and a 52-week high of $2.59. The stock has a market capitalization of $6.84 million, a P/E ratio of -0.14 and a beta of 1.47.
納斯達克奧迪的股票上週四以 0.11 美元開盤。該股票的 50 日移動平均價為 0.11 美元，其 200 日移動平均價為 0.32 美元。Otonomy 有 52 周的低點為 0.06 美元，52 周高點為 2.59 美元。該股的市值為 684 萬美元，市盈率為 -0.14，測試版為 1.47。
Institutional Trading of Otonomy
Otonomy 的機構交易
Several large investors have recently added to or reduced their stakes in OTIC. Dimensional Fund Advisors LP increased its position in Otonomy by 17.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock valued at $2,020,000 after acquiring an additional 126,747 shares during the period. Silverarc Capital Management LLC boosted its stake in shares of Otonomy by 0.6% during the 1st quarter. Silverarc Capital Management LLC now owns 1,207,385 shares of the biopharmaceutical company's stock worth $2,898,000 after acquiring an additional 7,571 shares in the last quarter. State Street Corp boosted its stake in shares of Otonomy by 5.1% during the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 8,839 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Otonomy in the third quarter worth $1,621,000. Finally, Lynx1 Capital Management LP raised its holdings in shares of Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares in the last quarter. 41.23% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近增加或減少了他們在奧迪的股份。維基金顧問 LP 在第一季度增加了 17.7% 在 Otonomy 的地位。維基金顧問有限公司在此期間額外收購 126,747 股股份後，擁有該生物製藥公司股票的 841,694 股，價值為 2,020,000 美元。銀弧資本管理有限責任公司在第一季度將其在 Otonomy 股份的股份提高了 0.6％。銀凱資本管理有限責任公司現在擁有該生物製藥公司股票的 1,207,385 股，價值 2,898,000 美元，在上個季度額外收購 7,571 股股票。在第一季度，州街公司將其在 Otonomy 股份的股份提高了 5.1％。州街公司現在擁有該生物製藥公司的 182,239 股股票，價值 437,000 美元，在上個季度額外收購 8,839 股股票。72 點資產管理有限責任公司在第三季度收購了一股價值 1,621,000 美元的 Otonomy 股份的新股份。最後，Lynx1 資本管理有限公司在第三季度將其對 Otonomy 股份的持有量增加了 7,609.6％。Lynx1 資本管理有限公司在上個季度額外收購 2,282,880 股股票後，現在擁有該生物製藥公司股票的 2,312,880 股，價值 682,000 美元。41.23% 的股票目前由機構投資者和對沖基金擁有。
About Otonomy
關於「音樂」
(Get Rating)
(取得評分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc 是一家生物製藥公司。從事神經病學治療藥物的開發。該公司的產品線包括奧替維克斯（地塞米松）梅尼爾氏病，奧替普利（環丙沙星懸浮液）急性中耳炎，帶管（AOMT），OTO-313（加基克列定）耳鳴，OTO-413（BDNF）隱性聽力損失，OTO-510（耳保護劑）防止耳朵重度損失（CIPHL），致聽力損失（CIHL）嚴重聽力損失（CIHL）。OTO-6XX
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免費獲取有關 OTONNOMY 的研究報告
- 床浴 & 超越是盤旋排水
- Allegro 微系統是定位良好的半導體股票
- 斯科茨奇蹟-格羅擊中底部，反轉在遊戲中
- 阿爾特里亞是一個巨大的經濟衰退股票，長期前景不確定
- 諾瓦克斯股價在 1 月份跳漲，而其他股票則下滑
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。